Iris Schrader
Praxis(EE)
Publications by Year
Research Areas
Breast Cancer Treatment Studies, Cancer Genomics and Diagnostics, Cancer Cells and Metastasis, HER2/EGFR in Cancer Research, Cancer Treatment and Pharmacology
Most-Cited Works
- → Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer(2009)1,771 cited
- → Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer(2012)530 cited
- → Detection and HER2 Expression of Circulating Tumor Cells: Prospective Monitoring in Breast Cancer Patients Treated in the Neoadjuvant GeparQuattro Trial(2010)487 cited
- → Prospective Validation of Immunological Infiltrate for Prediction of Response to Neoadjuvant Chemotherapy in HER2-Negative Breast Cancer – A Substudy of the Neoadjuvant GeparQuinto Trial(2013)224 cited
- → Neoadjuvant bevacizumab and anthracycline–taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44)(2013)151 cited
- → Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44–GeparQuinto)(2014)137 cited
- → HER2 Dimerization Inhibitor Pertuzumab - Mode of Action and Clinical Data in Breast Cancer(2013)117 cited
- → Prognostic Impact of Circulating Tumor Cells for Breast Cancer Patients Treated in the Neoadjuvant "Geparquattro" Trial(2017)113 cited
- → Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: results of a multicentre phase III trial(2005)110 cited
- → Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer—results from the GeparQuattro study (GBG 40)(2011)61 cited